Get Updates
Get Updates
Menu

A new dual-agent treatment for managing presbyopia

YUVEZZI combines two active ingredients, carbachol and brimonidine tartrate, that work together to deliver consistent and durable pupil modulation1

A less-fuss way to manage presbyopia

  • Significantly more patients achieved >3-line gain in BUCNVA without >1-line loss in BUCDVA with YUVEZZI than with vehicle or monotherapies1*

  • YUVEZZI achieves miosis from 30 minutes up to 10 hours with one drop, once a day1

  • 6x greater improvement in reading speed with YUVEZZI vs vehicle2†

  • Proven long-term safety with no observed retinal detachments over 12 months² 

  • Patients taking YUVEZZI reported less hyperemia (2.8%) than carbachol alone (10.7%)² 

Woman with presbyopia reading without glasses

*The efficacy of YUVEZZI was evaluated in 618 patients (aged 45 to 80) with presbyopia in two Phase 3 randomized, double-masked, controlled studies. Primary endpoint at hour 1: gain from baseline of >3 lines (15 letters) in binocular uncorrected near visual acuity (BUCNVA) without a loss of >1 line (5 letters) in binocular uncorrected distance visual acuity (BUCDVA).
† Compared to pre-baseline dose. Measured at day 90.

Sign up to receive updates on YUVEZZI product availability and other useful resources for your practice

Loading form…